Is fenofibrate a reasonable treatment for diabetic microvascular disease? (Q30372692)

21 June 2017

1 reference

title

Is fenofibrate a reasonable treatment for diabetic microvascular disease? (English)

1 reference

21 June 2017

Rafael Simó

1

1 reference

21 June 2017

Olga Simó-Servat

series ordinal

2

1 reference

21 June 2017

Cristina Hernández

series ordinal

3

1 reference

21 June 2017

1 May 2015

1 reference

21 June 2017

Current diabetes report

1 reference

21 June 2017

15

1 reference

21 June 2017

24

1 reference

21 June 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-015-0599-0

21 June 2017

0 references

cites work

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Global estimates of diabetes prevalence for 2013 and projections for 2035.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

The impact of diabetes mellitus on healthcare costs in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Costs of Diabetes Mellitus (CoDiM) in Germany, direct per-capita costs of managing hyperglycaemia and diabetes complications in 2010 compared to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Global prevalence and major risk factors of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Direct and indirect costs among employees with diabetic retinopathy in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Diabetic neuropathy: mechanisms to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate: treatment of hyperlipidemia and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Molecular Implications of the PPARs in the Diabetic Eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0599-0

The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study

21 January 2018

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Nephropathy in diabetes

1 reference

12 December 2020

Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

1 reference

12 December 2020

1 reference

12 December 2020

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

1 reference

12 December 2020

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

1 reference

12 December 2020

The consequences and costs of chronic kidney disease before ESRD

1 reference

12 December 2020

10.1007/S11892-015-0599-0

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1026660613

0 references

Fatcat ID

release_qgabpmvnjbh6rjnag3j2j2q4p4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qgabpmvnjbh6rjnag3j2j2q4p4

24 November 2022

mapped directly with Wikidata item

1 reference